

## Special Issue

# Cancer Associated Coagulation

### Message from the Guest Editor

This Special Issue aims to encompass research in all aspects of cancer-associated coagulation, from understanding the mechanisms of tumour-driven hypercoagulopathy to advances in anticoagulant treatment and patient management. Certain tumours, such as those of the pancreas and ovaries, are associated with an increased risk of the patient developing venous thromboembolism and this risk increases further with chemotherapy by mechanisms currently being investigated. Patients are managed with the use of anticoagulants such as low-molecular-weight heparin or orally administered alternatives. Of particular interest is the role of extracellular vesicles within these processes, although studies on all aspects of cancer-associated coagulation are welcome.

---

### Guest Editor

Dr. Leigh A. Madden

Department of Biomedical Science, The University of Hull, Hull HU6 7RX, UK

---

### Deadline for manuscript submissions

1 March 2025



## Hemato

---

an Open Access Journal  
by MDPI

---

Impact Factor 0.9  
CiteScore 1.3



[mdpi.com/si/64191](https://mdpi.com/si/64191)

*Hemato*  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
hemato@mdpi.com

[mdpi.com/journal/  
hemato](https://mdpi.com/journal/hemato)





# Hemato

---

an Open Access Journal  
by MDPI

---

Impact Factor 0.9  
CiteScore 1.3



[mdpi.com/journal/  
hemato](https://mdpi.com/journal/hemato)



## About the Journal

### Message from the Editor-in-Chief

---

#### Editor-in-Chief

Prof. Dr. Antonino Carbone

Professor of Pathology, Former Chairman of Department of Pathology,  
Centro di Riferimento Oncologico (CRO) Aviano, National Cancer  
Institute, Aviano, Italy

---

#### Author Benefits

##### Open Access:

free for readers, with article processing charges (APC) paid  
by authors or their institutions.

##### High Visibility:

indexed within ESCI (Web of Science), Scopus, EBSCO,  
and other databases.

##### Rapid Publication:

manuscripts are peer-reviewed and a first decision is  
provided to authors approximately 22.2 days after  
submission; acceptance to publication is undertaken in 6.9  
days (median values for papers published in this journal in  
the first half of 2024).